A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
Alphavirus
/ genetics
Angiotensin-Converting Enzyme 2
/ genetics
Animals
Antibodies, Neutralizing
/ biosynthesis
Antibodies, Viral
/ biosynthesis
CD8-Positive T-Lymphocytes
/ drug effects
COVID-19
/ immunology
COVID-19 Vaccines
/ administration & dosage
Female
Gene Expression
Humans
Immunity, Cellular
/ drug effects
Immunity, Humoral
/ drug effects
Interferon-gamma
/ genetics
Interleukin-4
/ genetics
Mice
Mice, Transgenic
Replicon
/ immunology
SARS-CoV-2
/ drug effects
Spike Glycoprotein, Coronavirus
/ chemistry
Th1 Cells
/ drug effects
Transgenes
Treatment Outcome
Vaccination
/ methods
Vaccines, Synthetic
/ administration & dosage
mRNA Vaccines
COVID-19
LUNAR-COV19
SARS-CoV-2
STARR
conventional mRNA
coronavirus
self-amplifying RNA
vaccine
Journal
Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581
Informations de publication
Date de publication:
02 06 2021
02 06 2021
Historique:
received:
19
02
2021
revised:
26
03
2021
accepted:
30
03
2021
pubmed:
7
4
2021
medline:
22
6
2021
entrez:
6
4
2021
Statut:
ppublish
Résumé
A self-transcribing and replicating RNA (STARR)-based vaccine (LUNAR-COV19) has been developed to prevent SARS-CoV-2 infection. The vaccine encodes an alphavirus-based replicon and the SARS-CoV-2 full-length spike glycoprotein. Translation of the replicon produces a replicase complex that amplifies and prolongs SARS-CoV-2 spike glycoprotein expression. A single prime vaccination in mice led to robust antibody responses, with neutralizing antibody titers increasing up to day 60. Activation of cell-mediated immunity produced a strong viral antigen-specific CD8
Identifiants
pubmed: 33823303
pii: S1525-0016(21)00188-X
doi: 10.1016/j.ymthe.2021.04.001
pmc: PMC8019652
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
IL4 protein, human
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Synthetic
0
spike protein, SARS-CoV-2
0
Interleukin-4
207137-56-2
Interferon-gamma
82115-62-6
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1970-1983Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests D.M., E.C.A., P.H., K.-J.J.P., M.A., H.B., A.D., Y.B., B.C., J.V., S.R, J.A.G., M.S., R.Y., W.T., K.T., S.P., P.K., J.D., S.M.S., B.M.S, S.G.H., and P.C. are employees of Arcturus Therapeutics, Inc. E.E.O is an unpaid member of the Scientific Advisory Board of Arcturus Therapeutics, Inc.